Literature DB >> 25438467

A phase IB clinical trial with Dekavil (F8-IL10), an immunoregulatory 'armed antibody' for the treatment of rheumatoid arthritis, used in combination wiIh methotrexate.

M Galeazzi, L Bazzichi, G D Sebastiani, D Neri, E Garcia, N Ravenni, L Giovannoni, J Wilton, M Bardelli, C Baldi, E Selvi, A Iuliano, G Minisola, R Caporali, E Prisco, S Bombardieri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25438467

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


× No keyword cloud information.
  15 in total

Review 1.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

2.  Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells.

Authors:  Liv Johannessen; Thomas B Sundberg; Daniel J O'Connell; Raivo Kolde; James Berstler; Katelyn J Billings; Bernard Khor; Brinton Seashore-Ludlow; Anne Fassl; Caitlin N Russell; Isabel J Latorre; Baishan Jiang; Daniel B Graham; Jose R Perez; Piotr Sicinski; Andrew J Phillips; Stuart L Schreiber; Nathanael S Gray; Alykhan F Shamji; Ramnik J Xavier
Journal:  Nat Chem Biol       Date:  2017-08-14       Impact factor: 15.040

Review 3.  Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins.

Authors:  Christian Fercher; Sahar Keshvari; Michael A McGuckin; Ross T Barnard
Journal:  Exp Biol Med (Maywood)       Date:  2017-12-19

Review 4.  Targeting IL-10 Family Cytokines for the Treatment of Human Diseases.

Authors:  Xiaoting Wang; Kit Wong; Wenjun Ouyang; Sascha Rutz
Journal:  Cold Spring Harb Perspect Biol       Date:  2019-02-01       Impact factor: 10.005

Review 5.  Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation.

Authors:  Patrizia Murer; Dario Neri
Journal:  N Biotechnol       Date:  2019-04-13       Impact factor: 5.079

Review 6.  Systematic Review: Targeted Molecular Imaging of Angiogenesis and Its Mediators in Rheumatoid Arthritis.

Authors:  Fatemeh Khodadust; Aiarpi Ezdoglian; Maarten M Steinz; Judy R van Beijnum; Gerben J C Zwezerijnen; Gerrit Jansen; Sander W Tas; Conny J van der Laken
Journal:  Int J Mol Sci       Date:  2022-06-25       Impact factor: 6.208

Review 7.  Location, location, location: how the tissue microenvironment affects inflammation in RA.

Authors:  Christopher D Buckley; Caroline Ospelt; Steffen Gay; Kim S Midwood
Journal:  Nat Rev Rheumatol       Date:  2021-02-01       Impact factor: 20.543

Review 8.  Systemically Administered, Target Organ-Specific Therapies for Regenerative Medicine.

Authors:  Tero A H Järvinen; Ulrike May; Stuart Prince
Journal:  Int J Mol Sci       Date:  2015-09-30       Impact factor: 5.923

Review 9.  Addressing the Immunogenicity of the Cargo and of the Targeting Antibodies with a Focus on Demmunized Bacterial Toxins and on Antibody-Targeted Human Effector Proteins.

Authors:  Yehudit Grinberg; Itai Benhar
Journal:  Biomedicines       Date:  2017-06-02

Review 10.  Cell-Type Targeted NF-kappaB Inhibition for the Treatment of Inflammatory Diseases.

Authors:  Bettina Sehnert; Harald Burkhardt; Stefan Dübel; Reinhard E Voll
Journal:  Cells       Date:  2020-07-06       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.